Hematopoietic stem cell transplantation during the COVID-19 pandemic with reference to EBMT recommendation
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and was classified as a pandemic by the World Health Organization in March 2020. However, its clinical manifestations and optimal management in immunosuppressed patients, including recipients of hematopoietic stem cell transplantation (HSCT), are unknown. There have been some international guidelines for the management of COVID-19 in HSCT recipients. In this issue, we describe the Japanese real-world clinical condition and careful points, explaining those international guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 62(2021), 2 vom: 01., Seite 106-114 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Atsuta, Yuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogeneic hematopoietic stem cell transplantation |
|---|
| Anmerkungen: |
Date Completed 10.03.2021 Date Revised 10.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.62.106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322360021 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322360021 | ||
| 003 | DE-627 | ||
| 005 | 20231225181858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.62.106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322360021 | ||
| 035 | |a (NLM)33678769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Atsuta, Yuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hematopoietic stem cell transplantation during the COVID-19 pandemic with reference to EBMT recommendation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2021 | ||
| 500 | |a Date Revised 10.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and was classified as a pandemic by the World Health Organization in March 2020. However, its clinical manifestations and optimal management in immunosuppressed patients, including recipients of hematopoietic stem cell transplantation (HSCT), are unknown. There have been some international guidelines for the management of COVID-19 in HSCT recipients. In this issue, we describe the Japanese real-world clinical condition and careful points, explaining those international guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 700 | 1 | |a Doki, Noriko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 62(2021), 2 vom: 01., Seite 106-114 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2021 |g number:2 |g day:01 |g pages:106-114 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.62.106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2021 |e 2 |b 01 |h 106-114 | ||